氨己烯酸功效和作用

The global average incidence of epilepsy is about 0.6%, one-third of which are refractory. Vigabatrin is the FDA's first drug to treat infantile spasms. In the past two years, more and more children with TSC have effectively controlled epilepsy through the use of vigabatrin tablets, especially infantile spasms. Western countries even use Vigabatrin to prevent brain abnormalities in children with TSC who have not yet developed the disease. Vigabatrin was approved for treatment in the UK in 1989. On August 21, 2009, the U.S. FDA approved Vigabatrin for the monotherapy of pediatric patients 1 month to 2 years old, where the potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjuvant (additional) treatment (CPS) for adult patients with refractory complex partial epilepsy. On January 16, 2019, the FDA approved the launch of a generic version of vigabatrin.

Clinical trials explore the therapeutic effect of the rare disease drug Vigabatrin on refractory epilepsy in children. The efficacy and safety of Sabril in 25 children were observed using the method of drug augmentation test. Two months after taking the medicine, the total effective rate was 68.0%. There were 24 patients who took the medicine for ≥4 months, and the total effective rate was 70.8%. After taking Vigabatrin, the blood concentration of phenobarbital is lower than the level before taking the drug. The serum alanine aminotransferase level was lower than before taking the medicine. No toxic or side effects were seen in 32 cases. 2 cases developed mild dizziness and drowsiness in the early stage after taking the medicine, which resolved spontaneously; 1 case developed severe restlessness and terminated treatment. Observation results show that Vigabatrin is more effective in treating refractory epilepsy in children.

Treatment with Vigabatrin may cause vision loss. Onset of vision loss is unpredictable and can occur within a few weeks of starting treatment with Sabril, or earlier, or at any time during treatment (even months or years later), and may occur after stopping treatment with Sabril. Vision evaluation is recommended at baseline (no later than 4 weeks after starting treatment), at least every 3 months of treatment, and approximately 3-6 months after stopping treatment. If vision loss is documented, consider discontinuing the drug, balancing benefits and risks. Sabril should not be treated in patients with other types of irreversible vision loss or in patients at high risk for it unless the benefits of Sabril treatment clearly outweigh the risks.

The above is the introduction about Vigabatrin, I hope it can help everyone.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related hot articles